Matt Meyerson headshot

Matt Meyerson

Charles A. Dana Chair in Human Cancer Genetics, Dana-Farber Cancer Institute
Professor of Genetics and Medicine, Harvard Medical School
Director, Center for Cancer Genomics, Dana-Farber Cancer Institute
Dana Farber Cancer Institute
617-632-4377
Meyerson Lab
XRN1 deletion induces PKR-dependent cell lethality in interferon-activated cancer cells.
Authors: Authors: Zou T, Zhou M, Gupta A, Zhuang P, Fishbein AR, Wei HY, Zhang Z, Cherniack AD, Meyerson M.
bioRxiv
View full abstract on Pubmed
Bifunctional small molecules that induce nuclear localization and targeted transcriptional regulation.
Authors: Authors: Gibson WJ, Sadagopan A, Shoba VM, Choudhary A, Meyerson M, Schreiber SL.
bioRxiv
View full abstract on Pubmed
Cancer aneuploidies are shaped primarily by effects on tumour fitness.
Authors: Authors: Shih J, Sarmashghi S, Zhakula-Kostadinova N, Zhang S, Georgis Y, Hoyt SH, Cuoco MS, Gao GF, Spurr LF, Berger AC, Ha G, Rendo V, Shen H, Meyerson M, Cherniack AD, Taylor AM, Beroukhim R.
Nature
View full abstract on Pubmed
Molecular portraits of lung cancer evolution.
Authors: Authors: Hayes TK, Meyerson M.
Nature
View full abstract on Pubmed
Ultrasensitive detection of circulating LINE-1 ORF1p as a specific multi-cancer biomarker.
Authors: Authors: Taylor MS, Connie W, Fridy PC, Zhang SJ, Senussi Y, Wolters JC, Cheng WC, Heaps J, Miller BD, Mori K, Cohen L, Jiang H, Molloy KR, Norden BL, Chait BT, Goggins M, Bhan I, Franses JW, Yang X, Taplin ME, Wang X, Christiani DC, Johnson BE, Meyerson M, Uppaluri R, Egloff AM, Denault EN, Spring LM, Wang TL, Shih IM, Jung E, Arora KS, Zukerberg LR, Yilmaz OH, Chi G, Matulonis UA, Song Y, Nieman L, Parikh AR, Strickland M, Corcoran RB, Mustelin T, Eng G, Yilmaz ÃH, Skates SJ, Rueda BR, Drapkin R, Klempner SJ, Deshpande V, Ting DT, Rout MP, LaCava J, Walt DR, Burns KH.
bioRxiv
View full abstract on Pubmed
Author Correction: Genomic basis for RNA alterations in cancer.
Authors: Authors: Calabrese C, Davidson NR, Demircioglu D, Fonseca NA, He Y, Kahles A, Lehmann KV, Liu F, Shiraishi Y, Soulette CM, Urban L, Greger L, Li S, Liu D, Perry MD, Xiang Q, Zhang F, Zhang J, Bailey P, Erkek S, Hoadley KA, Hou Y, Huska MR, Kilpinen H, Korbel JO, Marin MG, Markowski J, Nandi T, Pan-Hammarström Q, Pedamallu CS, Siebert R, Stark SG, Su H, Tan P, Waszak SM, Yung C, Zhu S, Awadalla P, Creighton CJ, Meyerson M, Ouellette BFF, Wu K, Yang H, Brazma A, Brooks AN, Göke J, Rätsch G, Schwarz RF, Stegle O, Zhang Z.
Nature
View full abstract on Pubmed
Telomerase inhibition is an effective therapeutic strategy in TERT promoter mutant-glioblastoma models with low tumor volume.
Authors: Authors: Aquilanti E, Kageler L, Watson J, Baird DM, Jones RE, Hodges M, Szegletes ZM, Doench JG, Strathdee CA, McFaline Figueroa JR, Ligon K, Beck M, Wen PY, Meyerson M.
Neuro Oncol
View full abstract on Pubmed
Correction to "Discovery and Structure-Based Design of Potent Covalent PPAR? Inverse-Agonists BAY-4931 and BAY-0069".
Authors: Authors: Orsi DL, Pook E, Bräuer N, Friberg A, Lienau P, Lemke CT, Stellfeld T, Brüggemeier U, Pütter V, Meyer H, Baco M, Tang S, Cherniack AD, Westlake L, Bender SA, Kocak M, Strathdee CA, Meyerson M, Eis K, Goldstein JT.
J Med Chem
View full abstract on Pubmed
Discovery and characterization of orally bioavailable 4-chloro-6-fluoroisophthalamides as covalent PPARG inverse-agonists.
Authors: Authors: Orsi DL, Ferrara SJ, Siegel S, Friberg A, Bouché L, Pook E, Lienau P, Bluck JP, Lemke CT, Akcay G, Stellfeld T, Meyer H, Pütter V, Holton SJ, Korr D, Jerchel-Furau I, Pantelidou C, Strathdee CA, Meyerson M, Eis K, Goldstein JT.
Bioorg Med Chem
View full abstract on Pubmed
Correction to: Oncogenic RIT1 mutations in lung adenocarcinoma.
Authors: Authors: Berger AH, Imielinski M, Duke F, Wala J, Kaplan N, Shi G-, Andres DA, Meyerson M.
Oncogene
View full abstract on Pubmed